{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Diseases%2C+Viral&page=17",
    "query": {
      "condition": "Skin Diseases, Viral",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 523,
    "total_pages": 53,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Diseases%2C+Viral&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Diseases%2C+Viral&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T11:00:37.480Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06216938",
      "title": "RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Vusolimogene oderparepvec (RP1)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Yana Najjar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-03-07",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06216938"
    },
    {
      "nct_id": "NCT05270135",
      "title": "ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Skin and Soft Tissue Infections",
        "Hiv",
        "Hepatitis C",
        "Bloodstream Infection"
      ],
      "interventions": [
        {
          "name": "ASAP",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2022-12-01",
      "completion_date": "2023-09-30",
      "has_results": false,
      "last_update_posted_date": "2023-12-19",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05270135"
    },
    {
      "nct_id": "NCT00612222",
      "title": "Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALVAC MART-1 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2008-01",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2015-10-28",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00612222"
    },
    {
      "nct_id": "NCT03277703",
      "title": "Flu Vaccine Response in Patients on Biologic Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatologic Disorder",
        "Inflammatory Bowel Diseases",
        "Immune Complex Diseases"
      ],
      "interventions": [
        {
          "name": "Influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "3 Years to 22 Years"
      },
      "enrollment_count": 30,
      "start_date": "2017-11-03",
      "completion_date": "2019-12-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 1,
      "location_summary": "East Setauket, New York",
      "locations": [
        {
          "city": "East Setauket",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03277703"
    },
    {
      "nct_id": "NCT00973856",
      "title": "Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Papillomavirus Infections",
        "Warts",
        "Condylomata Acuminata",
        "Epidermodysplasia Verruciformis"
      ],
      "interventions": [
        {
          "name": "PURELL VF481",
          "type": "OTHER"
        },
        {
          "name": "Placebo Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Cleveland Clinic Akron General",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 5,
      "start_date": "2009-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 1,
      "location_summary": "Akron, Ohio",
      "locations": [
        {
          "city": "Akron",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00973856"
    },
    {
      "nct_id": "NCT02669862",
      "title": "A Study of A-101 Solution in Subjects With Common Warts.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Common Warts"
      ],
      "interventions": [
        {
          "name": "A-101 Solution 40",
          "type": "DRUG"
        },
        {
          "name": "A-101 Solution 45",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2015-12-21",
      "completion_date": "2016-09-16",
      "has_results": true,
      "last_update_posted_date": "2018-12-07",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 1,
      "location_summary": "Wayne, Pennsylvania",
      "locations": [
        {
          "city": "Wayne",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02669862"
    },
    {
      "nct_id": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Astrocytoma, IDH-Mutant",
        "Glioblastoma, IDH-wildtype",
        "Brain Metastases, Adult",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Microsatellite Instability-High Solid Malignant Tumor",
        "Mismatch Repair Deficient Solid Malignant Tumor",
        "Microsatellite Instability-High Colorectal Cancer",
        "Mismatch Repair Deficient Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Small Cell Lung Cancer",
        "Squamous Cell Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "NEO212 Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI Protocol",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neonc Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2023-11-01",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06047379"
    },
    {
      "nct_id": "NCT00071942",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant vaccinia-MUC1 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant vaccinia-TRICOM vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2003-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-11",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071942"
    },
    {
      "nct_id": "NCT00100698",
      "title": "Physiologic Growth Hormone Effects in HIV Lipodystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "AIDS",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "recombinant human growth hormone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 56,
      "start_date": "2004-01",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2010-07-27",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100698"
    },
    {
      "nct_id": "NCT00942084",
      "title": "A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Simplex Virus",
        "Neonatal Sepsis"
      ],
      "interventions": [
        {
          "name": "Acyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phillip Brian Smith",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Days",
        "sex": "ALL",
        "summary": "Up to 45 Days"
      },
      "enrollment_count": 32,
      "start_date": "2011-09",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-10-25T11:00:37.480Z",
      "location_count": 3,
      "location_summary": "Wichita, Kansas • New Orleans, Louisiana • Durham, North Carolina",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00942084"
    }
  ]
}